Exosome Isolation Service
- Sample Type Adaptation: Design pre-filtration processes for cell debris and free proteins based on the sample type (e.g., plasma, urine, cell culture medium).
- Stability Control: Add protease inhibitors and maintain low-temperature cold chain transportation to prevent exosome degradation.
- For High Purity: Ultracentrifugation (UC) + Immunoaffinity Capture (IAC) for impurity removal.
- For Clinical Micro Samples: Microfluidic chip technology for efficient recovery of micro-sized samples.
- For Rapid Screening: Precipitation method (PEG) optimized for rapid crude exosome isolation within a few hours.
- Particle Characterization: NanoSight (NTA) to measure particle size distribution (30-150 nm) and Zeta potential detection.
- Marker Validation: Western blot to detect exosome-specific proteins such as Alix, TSG101, CD9.
- Morphological Confirmation: Transmission electron microscopy (TEM) to observe typical "cup-shaped" structure and ensure integrity.
- Standardized Cryopreservation: Provide -80°C frozen exosome suspensions (optional lysis treatment), suitable for proteomics, RNA sequencing, and functional assays.
- Data Integrity: Full separation report including concentration, purity, marker validation images, and electron microscope images.
- Covers both traditional methods (UC, DG) and emerging technologies (affinity capture, microfluidics).
- Supports efficient separation from as low as 0.5 mL plasma samples.
- Customize lysis protocols or preserve complete vesicles according to downstream experimental needs (e.g., drug delivery research, proteomics).
- Special treatment for clinical samples: lipid removal pre-treatment for hyperlipidemia patients' plasma, etc.
- Cancer Liquid Biopsy: Isolate tumor-derived exosomes (e.g., EpCAM+) from plasma, analyze PD-L1 expression levels to assess immune therapy response.
- Neurological Disease Research: Exosome isolation from cerebrospinal fluid, enriching neuron-specific markers (e.g., L1CAM), exploring Alzheimer’s disease biomarkers.
- Drug Delivery Development: Leverage the natural targeting ability of exosomes to provide high-purity carriers for gene/drug loading verification.
Exosomes are nanoscale (30-150 nm) extracellular vesicles actively secreted by cells, encapsulating the "biological information package" of the source cell, including proteins, lipids, functional mRNA, microRNA, and DNA fragments. They act as "messengers" for intercellular communication and participate in regulating key physiological and pathological processes such as immune response, tumor metastasis, and tissue regeneration. In recent years, exosomes have become a cutting-edge focus in the fields of disease diagnosis, prognosis monitoring, and drug delivery, due to their stability in body fluids (such as blood and urine). Efficient isolation of high-purity exosomes is the first step from basic research to clinical applications. Traditional methods such as ultracentrifugation (UC) and density gradient separation (DG) achieve separation through physical sedimentation but face challenges such as long processing times, large sample volumes, and low purity. Immunoaffinity capture methods (such as antibody magnetic beads) target specific antigens (e.g., EpCAM, CD63) for directed exosome enrichment but require specific marker design. Recently emerging technologies (such as microfluidic chips, acoustic screening) combine multi-dimensional approaches (size selection + surface markers) to significantly improve yield efficiency and precision.
Chen, J. et al. Front Bioeng Biotechnol. 2022.
Figure 1. Schematic Representation of Common Exosomal Separation Techniques
High-quality exosome isolation is the cornerstone for ensuring the reliability of downstream analyses (such as proteomics and functional validation). However, the complexity of clinical or research samples (e.g., lipoproteins and cellular debris in blood) and the heterogeneity of exosomes greatly increase the difficulty of separation. Low-purity isolation may result in contamination with apoptotic bodies or microvesicles, leading to data analysis bias or misleading conclusions. Therefore, selecting an efficient and reproducible isolation method is crucial to advancing precision medicine.
Focused on exosome technology development, MtoZ Biolabs offers high-purity, high-yield exosome isolation service with standardized processes, multi-technology integration, and stringent quality control systems. Whether for clinical body fluid samples (serum, cerebrospinal fluid), cell culture supernatants, or complex tissue samples, we can customize solutions to help you overcome separation technology bottlenecks and accelerate research translation and clinical exploration!
Analysis Workflow
1. Sample Evaluation & Pre-treatment
2. Multi-Technology Separation
3. Precise Quality Validation
4. Delivery & Downstream Compatibility
Service Advantages
1. Technology Platform-Flexibly Matching Needs
2. Dual Guarantee of Purity and Yield
Uses gradient separation combined with affinity purification technology, achieving <5% impurity contamination and exosome recovery rate of over 80% (based on NTA quantification).
3. Personalized Customization Services
Applications
Deliverables
1. Exosome concentration, particle size distribution report (NTA), marker Western blot validation images.
2. Morphological verification: Transmission electron microscopy original images and analysis.
3. Protein quantification: BCA total protein quantification, marker semi-quantitative analysis.
4. Personalized analysis: Exosome subpopulation sorting.
Exosome research success begins with attention to every detail. MtoZ Biolabs places "precise separation, driving discovery" at the core, offering a solid technical foundation for your exosome research through multi-dimensional technology integration, a strict quality control system, and deep clinical scenario adaptation. Whether exploring disease mechanisms, developing new diagnostic and therapeutic tools, or validating drug delivery systems, choose MtoZ's Exosome Isolation Service to simplify complex problems!
How to order?
